This study involves a number of different medications.
Ciforadenant is an experimental immunotherapy drug that works by blocking the receptor for a molecule called Adenosine. This allows the body to trigger a stronger immune response against cancerous cells.
The other drug in this study is called Atezolizumab (Tecentriq®), which is a Health Canada-approved immunotherapy treatment for kidney cancer. This drug works by targeting a molecule called PD-L1 which enable the immune system to better recognize and destroy cancer cells.
This study will investigate the safety and effectiveness of MBG453 used by itself, as well as in combination with PDR001. Accordingly, you may be randomly enrolled in one of two groups:
- Ciforadenant alone
- Ciforadenant with Atezolizumab
In order to maximize effectiveness and minimize side effects, difference doses of each drug may be used to determine the optimal dosage of these medications.
- Clear cell kidney cancer
- Cancer has spread or cannot be removed by surgery
- May have had 1, but not more than 5 prior drug therapies
- At least one of these therapies must have been a type of PD-L1 inhibitor
Additional eligibility criteria will apply. Please speak to your doctor.
Find out more about this study.
|Hospital / Cancer Centre||Principal Investigator||Location||Trial Status|
|Hospital / Cancer CentreBC Cancer Agency||Principal InvestigatorDr. Daniel Renouf||LocationVancouver, BC||Trial StatusCompleted|
|Hospital / Cancer CentreCross Cancer Institute||Principal InvestigatorDr. Michael Chu||LocationEdmonton, AB||Trial StatusCompleted|
|Hospital / Cancer CentreOttawa Hospital Cancer Centre||Principal InvestigatorDr. Rachel Goodwin||LocationOttawa, ON||Trial StatusCompleted|